anagliptin

Anagliptin is a small molecule, orally active antidiabetic drug that acts as a potent and selective inhibitor of dipeptidyl peptidase 4 (DPP-4). By inhibiting DPP-4, anagliptin increases the half-life of incretin hormones such as GLP‑1 and GIP, which stimulates insulin secretion from pancreatic β-cells and suppresses glucagon release from α-cells in response to food intake. This mechanism leads to improved glycemic control in adults with type 2 diabetes. Anagliptin has also demonstrated lipid-lowering effects, potentially through downregulation of SREBP activity and decreased hepatic lipid synthesis. It is approved for use in Japan since 2012 for type 2 diabetes mellitus, both as monotherapy and combination therapy[3][5][6]. The primary indication is glycemic control in type 2 diabetes; it may also have beneficial effects on cholesterol levels[4][6].

Brand names

Suiny

Other names

anagliptin739366-20-2Anagliptin [INN]